# Christopher E. Brightling

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/christopher-e-brightling/

## Facts

| Field | Value |
| --- | --- |
| Citations | 78,955 |
| Field | Asthma and respiratory diseases |
| h-index | 133 |
| i10-index | 520 |
| Last Known Institution | University of Leicester |
| OpenAlex ID | https://openalex.org/A5048320859 |
| ORCID iD | https://orcid.org/0000-0002-9345-4903 |
| Works | 1,146 |

## Researcher papers

- [Dexamethasone in Hospitalized Patients with Covid-19.](https://scholariq.org/papers/dexamethasone-in-hospitalized-patients-with-covid-19/)
- [Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study](https://scholariq.org/papers/physical-cognitive-and-mental-health-impacts-of-covid-19-after-hospitalisation/)
- [Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs](https://scholariq.org/papers/allergic-rhinitis-and-its-impact-on-asthma-aria-achievements-in-10-years-and/)
- [Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge](https://scholariq.org/papers/medium-term-effects-of-sars-cov-2-infection-on-multiple-vital-organs-exercise/)
- [Multiancestry association study identifies new asthma risk loci that colocalize with immune-cell enhancer marks](https://scholariq.org/papers/multiancestry-association-study-identifies-new-asthma-risk-loci-that-colocalize/)
- [Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study](https://scholariq.org/papers/clinical-characteristics-with-inflammation-profiling-of-long-covid-and/)
- [Benralizumab for the Prevention of COPD Exacerbations](https://scholariq.org/papers/benralizumab-for-the-prevention-of-copd-exacerbations/)
- [Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial](https://scholariq.org/papers/gefapixant-a-p2x3-receptor-antagonist-for-the-treatment-of-refractory-or/)
- [Integrated care pathways for airway diseases (AIRWAYS-ICPs)](https://scholariq.org/papers/integrated-care-pathways-for-airway-diseases-airways-icps/)
- [Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study](https://scholariq.org/papers/long-term-safety-and-efficacy-of-tezepelumab-in-people-with-severe-uncontrolled/)
- [SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination](https://scholariq.org/papers/sars-cov-2-specific-nasal-iga-wanes-9-months-after-hospitalisation-with-covid-19/)

## Researcher topics

- [Asthma and respiratory diseases](https://scholariq.org/topics/asthma-and-respiratory-diseases/)
- [Chronic Obstructive Pulmonary Disease (COPD) Research](https://scholariq.org/topics/chronic-obstructive-pulmonary-disease-copd-research/)
- [Respiratory and Cough-Related Research](https://scholariq.org/topics/respiratory-and-cough-related-research/)
- [Pediatric health and respiratory diseases](https://scholariq.org/topics/pediatric-health-and-respiratory-diseases/)
- [IL-33, ST2, and ILC Pathways](https://scholariq.org/topics/il-33-st2-and-ilc-pathways/)

## Researcher university

- [University of Leicester](https://scholariq.org/institutions/university-of-leicester/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.